Status:
UNKNOWN
Resynchronisation Therapy of Right Ventricle in Pulmonary Arterial Hypertension
Lead Sponsor:
University Hospital, Caen
Conditions:
Pulmonary Arterial Hypertension
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Pulmonary arterial hypertension is a disease characterised by pathological changes in the pulmonary arteries leading to a progressive increase in pulmonary vascular resistance and pulmonary artery pre...
Eligibility Criteria
Inclusion
- Pulmonary hypertension type I, III, IV, V Dana Point classification
- NYHA classification equal or superior to stage II
- During right catetherization : cardiac index inferior or equal 2.5 L/mn/m2 and atrial pressure superior or equal 10 mmHg OR cardiac index equal or inferior to 2.2 L/mn/m2
- Optimal therapy considered by the referring specialist practioner of the patient
Exclusion
- Minor or incapacitated adult
- Pregnancy
- Unability to give free and informed consent
- Pulmonary hypertension type II Dana Point classification
- Eisenmenger syndrome
- Patent foramen ovale
- Left bundle-brach block
- Pulmonary hypertension exacerbation
- Medical clinical situation considered inappropriate by the investigator
- Patient eligible for a heart-lung transplant
- Patient eligible for pulmonary endarterectomy
- Patient with poor echogenicity
- Filter in the inferior vena cava
Key Trial Info
Start Date :
July 1 2013
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
June 1 2014
Estimated Enrollment :
15 Patients enrolled
Trial Details
Trial ID
NCT01905189
Start Date
July 1 2013
End Date
June 1 2014
Last Update
April 9 2014
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Caen UH
Caen, Basse-Normandie, France, 14000